Pediatric psoriasis treatment challenges
Investigators have found that there are limited options for treating pediatric psoriasis.
Psoriasis is not well recognized and treated among pediatric patients, according to a recent review.
Psoriasis is a chronic inflammatory disease that leads to skin manifestations. It is immune-mediated, but there are few medications approved for pediatric patients with psoriasis. In a recent review, the difficulties of diagnosing and treating pediatric psoriasis were discussed.
Investigators used a series of PubMed searches to discern articles pertaining to pediatric psoriasis, discussing topics such as epidemiology, treatment efficacy and safety, disease characteristics, and access to care.
The articles showed that it can be difficult to clinically diagnose psoriasis, and that patients often have trouble getting treatment. The medications which have been approved are often for adults and are not proven safe and efficient for pediatric use. This leaves pediatric patients with limited options for psoriasis treatment.
Though more trials are attempting to use biological agents for pediatric psoriasis, they may lead to concerns about applying these medications for pediatric use. Investigators concluded that clinicians must balance the risks and benefits for a treatment plan in pediatric patients.
Reference
Hebert AA, Browning J, Kwong PC, Duarte AM, Price HN, Siegfried E. Managing pediatric psoriasis: update on treatments and challenges-a review. J Dermatolog Treat. 2022;33(5):2433-2442. doi:10.1080/09546634.2022.2059051
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa
November 28th 2023The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.
